Particle.news
Download on the App Store
3 ARTICLES
·
4w ago

FDA’s Vinay Prasad Reclaims Chief Medical and Scientific Officer Title

The move consolidates his influence over biologics policy, including choices for accelerated reviews.

FILE PHOTO; Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/ File Photo
Image

Overview

  • The FDA website now lists Prasad as chief medical and scientific officer in addition to his role leading the Center for Biologics Evaluation and Research.
  • Health and Human Services spokesperson Rich Danker confirmed his reappointment to the top medical and scientific position.
  • Prasad returned on Aug. 9 to head CBER, where he oversees vaccines, cell and gene therapies, and blood products.
  • The restored title includes representing the agency on scientific matters and a leadership role in selecting companies for a program that accelerates certain drug reviews aligned with FDA priorities.
  • His reinstatement follows a July 29 departure after conservative criticism tied to safety actions on Sarepta’s gene therapy, as well as earlier controversies over stricter evidence demands for Covid vaccine updates and staff overrulings.